Sirukumab

From WikiProjectMed
Jump to navigation Jump to search
Sirukumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetIL6
Clinical data
ATC code
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6450H9926N1690O1998S46
Molar mass144588.95 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Sirukumab (INN, USAN) (developmental code name CNTO-136, tentative brand name Plivensia) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.[1] It acts against the proinflammatory cytokine Interleukin 6 (IL-6).[2]

Sirukumab is currently under development by Johnson & Johnson's subsidiary Centocor.[3]

Clinical trials

Rheumatoid arthritis

It has started clinical trials.[4] and reported some phase II results.[3]

In December 2015 three phase III trials (SIRROUND-D, -H and -T) were collecting data.[5] By Feb 2017 SIRROUND-D was considered to have met both co-primary endpoints.[6]

Other

The drug was previously under development for the treatment of depression.[7]

See also

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab" (PDF). American Medical Association.
  2. ^ Bartoli F, Bae S, Cometi L, Matucci Cerinic M, Furst DE (July 2018). "Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018". Expert Review of Clinical Immunology. 14 (7): 539–547. doi:10.1080/1744666X.2018.1487291. PMID 29925278. S2CID 49330982.
  3. ^ a b "Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis". PR News Wire. Cision. 25 May 2011.
  4. ^ Clinical trial number NCT00718718 for "A Study of the Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy" at ClinicalTrials.gov
  5. ^ House DW (16 December 2015). "Glaxo says top-line results positive in late-stage study of sirukumab in rheumatoid arthritis". Seeking Alpha.
  6. ^ "IL-6 in RA: What Predicts Non-Progression? - High-risk patients showed most benefit with sirukumab". January 2017.
  7. ^ "Sirukumab - Janssen Biotech". AdisInsight. Springer Nature Switzerland AG.